静脉滴注联合不同口服药物治疗糖尿病周围神经病变的疗效及安全性
2016-01-11王超群,邹俊杰,汤玮等
·论著·
静脉滴注联合不同口服药物治疗糖尿病周围神经病变的疗效及安全性
王超群,邹俊杰,汤玮,卢晓晓,刘子毓,刘志民*(第二军医大学长征医院内分泌科,上海 200003)
[摘要]目的:探讨糖尿病周围神经病变(diabetic peripheral neuropathy,DPN)在静脉给药治疗联合不同口服药物的疗效维持时间及安全性。方法:将180例DPN病人予静脉滴注甲钴胺、前列地尔、α-硫辛酸治疗15 d后,按性别分层随机分为5个口服药物组(A~E)和1个对照组(F),每组30例。口服药物组分别给予甲钴胺(A)、通心络胶囊(B)、西洛他唑(C)、贝前列素钠(D)、舒洛地特(E)3个月。分别在静脉滴注治疗前、静脉滴注治疗后15 d,口服药物后30、60、90 d对各组行症状评分[(total symptom scores(TSS)和number,severity,change(NSC)];静脉滴注治疗前、静脉滴注治疗后15 d、口服药物后90 d记录各组运动、感觉神经传导速度,并观察有无不良反应。结果:在口服药物治疗60 d后,与对照组相比,贝前列素钠和舒洛地特组TSS评分改善有统计学意义(P<0.05);口服药物治疗90 d后,与对照组相比,通心络、贝前列素钠和舒洛地特组TSS评分改善,差异有统计学意义(P<0.01)。口服药物90 d后,所有口服药物组与对照组相比,NSC评分、正中神经运动和感觉传导速度差异均有统计学意义(P<0.05)。结论:治疗DPN,静脉给药联合口服药物,特别是通心络胶囊、贝前列素钠、舒洛地特对静脉给药后的疗效维持效果显著,且安全性良好。
[关键词]糖尿病周围神经病变;口服药物;通心络胶囊;贝前列素钠;舒洛地特
[中图分类号]R587.2[文献标志码]A
DOI:10.5428/pcar20150210
基金项目国家自然科学基金(81170718),上海市自然科学基金(13ZR1414700)
作者简介王超群(男),硕士生.
[收稿日期]2015-01-06
Efficacy and safety of intravenous drip combined with different oral drugs in treatment of patients with diabetic peripheral neuropathy
WANG ChaoQun,ZOU JunJie,TANG Wei,LU XiaoXiao,LIU ZiYu,LIU ZhiMin*(Department of Endocrinology,Changzheng Hospital,Second Military Medical University,Shanghai 200003,China)
ABSTRACT[]Objective:To observe the duration of efficacy and safety of intravenous infusion combined with different oral drugs in treatment of patients with diabetic peripheral neuropathy (DPN).Methods:One hundred and eighty DPN patients were selected and given mecobalamine,alprostadil,α-lipoic acid by intravenous drip (ID)for 15 days.Then,according to sex bench,the patients were randomly divided into 5 oral medication groups (A-E) and one control group (F),each consisting of 30 patients.The oral medication groups were respectively given mecobalamin(A),Tongxinluo capsules(B),cilostazol(C),beraprost sodium(D) and sulodexide(E) for 3 months.Total symptom scores (TSS) and number,severity and change(NSC) in each group were observed before the ID,15 days post ID,as well as 30,60 and 90 days after oral medication.Motor and sensory nerve conduction velocities of various groups were recorded and seen if there were adverse reactions,before ID,15 days after ID,as well as 90 days after oral medication.Results:Sixty days after oral medication,TSS scores of groups D and E were lowered,as compared with those of the control group,with statistical significance (P<0.05).Ninety days after oral medication,TSS scores of groups B,D and E were also lower,as compared with those of the control group,and statistical significance could be noted when comparisons were made between the experimental groups and the control group (P<0.01).And 90 days after oral medication,NSC scores,the scores of the median nerve motor and sensory conduction velocities were increased in all the experimental groups,as compared with those of the control group (P<0.05).Conclusion: In the treatment of DPN patients,ID coupled with oral drugs,Tongxinluo capsules, beraprost sodium and sulodexide in particular,could significantly prolong treatment efficacy as a result of ID,and in the meantime,little adverse reactions could be noticed during the course of treatment.
[KEY WORDS]diabetic peripheral neuropathy;oral medication;Tongxinluo capsules;beraprost sodium;sulodexide
[Pharm Care Res,2015,15(2):119-122]
E-mail:wangcqvip@163.com
*通信作者(Corresponding author):刘志民,E-mail:zmliu_cz@hotmail.com
糖尿病周围神经病变(diabetic peripheral neuropathy,DPN)属于微血管并发症之一,其发病与循环障碍、代谢紊乱及氧化应激等有关,其病理改变为脱髓鞘及轴突改变,临床上治疗较为棘手。为此,作者探索各种药物的综合治疗,如神经修复剂甲钴胺(商品名 弥可保)、改善微循环药前列地尔(商品名 凯时)、抗氧化剂α-硫辛酸,观察疗效及不良反应。……
